Predict your next investment

Corporation
sinobioway.com.cn

See what CB Insights has to offer

Investments

4

Portfolio Exits

1

Partners & Customers

2

About Sinobioway

Sinobioway Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Sinobioway News

Tri Ethyl Phosphite Market Economic Impact Exhibiting Ravishing Growth in Globally to 2027 with Top Key Players:Eastman China Haohua Chemical Group Co., Ltd Shandong Sinobioway Biomedicine Corp., Ltd

Aug 15, 2021

Key Topics in this News Article: News Snapshot: Tri Ethyl Phosphite Market Economic Impact Exhibiting Ravishing Growth in Globally to 2027 with Top Key Players:Eastman China Haohua Chemical Group Co., Ltd Shandong Sinobioway Biomedicine Corp., Ltd The “ Global Tri Ethyl Phosphite Market ” is growing at an exciting pace driven by changing dynamics and risk ecosystem, a study of which forms the crux of the report. The study on the global Tri Ethyl Phosphite market takes a closer look at several regional trends and the emerging regulatory landscape to assess its prospects. The critical assessment of the numerous growth factors and breaks in the global Tri Ethyl...

Sinobioway Investments

4 Investments

Sinobioway has made 4 investments. Their latest investment was in Enerkem as part of their Series G on February 2, 2018.

CBI Logo

Sinobioway Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/6/2018

Series G

Enerkem

$223.89M

Yes

4

1/8/2018

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

1/6/2017

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/6/2016

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/6/2018

1/8/2018

1/6/2017

12/6/2016

Round

Series G

Series A - II

Series A

Partnership

Company

Enerkem

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$223.89M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

Sinobioway Portfolio Exits

1 Portfolio Exit

Sinobioway has 1 portfolio exit. Their latest portfolio exit was BioAtla on December 16, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/16/2020

IPO

$991

2

Date

12/16/2020

Exit

IPO

Companies

Valuation

$991

Acquirer

Sources

2

Sinobioway Partners & Customers

2 Partners and customers

Sinobioway has 2 strategic partners and customers. Sinobioway recently partnered with BioAtla on March 3, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

3/1/2015

Partner

BioAtla

United States

Week in Review: Shanghai Pharma Considers $4 Billion Bid for Germany's Stada

Beijing Sinobioway added five new Conditionally Active Biologic antibody targets to its collaboration with BioAtla , a San Diego-Beijing biotech .

11

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/1/2015

Type

Partner

Licensor

Business Partner

BioAtla

Country

United States

Subscribe to see more

News Snippet

Week in Review: Shanghai Pharma Considers $4 Billion Bid for Germany's Stada

Beijing Sinobioway added five new Conditionally Active Biologic antibody targets to its collaboration with BioAtla , a San Diego-Beijing biotech .

Subscribe to see more

Subscribe to see more

Sources

11

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.